Chromosome 1p loss evaluation in anaplastic oligodendrogliomas
- 6 May 2008
- journal article
- case report
- Published by Wiley in Neuropathology
- Vol. 28 (4) , 440-443
- https://doi.org/10.1111/j.1440-1789.2008.00863.x
Abstract
The chromosome (chr) 1p deletion is a favorable biomarker in oligodendroglial tumors and is even more powerful a marker when combined with chr 19q loss. As a result, the 1p deletion is taken into account more and more in clinical trials and the management of patients. However, the laboratory technique implemented for detection of this biomarker has been a topic of debate. To illustrate the usefulness of evaluating multiple loci, we here report two anaplastic oligodendrogliomas that were investigated using fluorescent in situ hybridization (FISH) and bacterial artificial chromosome (BAC)-array-based comparative genomic hybridization (aCGH). Indeed, segmental analysis using FISH, limited to chr 1p36 was unable to discriminate between complete and partial deletions of chrs 1p. However, complete and partial deletions of 1p are reported to have distinct clinical outcomes. Our results illustrate that aCGH (or other multiple loci technologies) provide complementary information to single locus technologies such as FISH because multiple loci technologies can evaluate the extent of the chr 1p deletion.Keywords
This publication has 19 references indexed in Scilit:
- 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatmentEuropean Journal Of Cancer, 2006
- Multiplex Ligation-Dependent Probe AmplificationThe Journal of Molecular Diagnostics, 2006
- Fluorescence In Situ Hybridization (FISH) on Touch Preparations: A Reliable Method for Detecting Loss of Heterozygosity at 1p and 19q in Oligodendroglial TumorsThe American Journal of Surgical Pathology, 2006
- Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III TrialJournal of Clinical Oncology, 2006
- Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402Journal of Clinical Oncology, 2006
- Spatial normalization of array-CGH dataBMC Bioinformatics, 2006
- Automatized assessment of 1p36-19q13 status in gliomas by interphase FISH assay on touch imprints of frozen tumoursActa Neuropathologica, 2006
- Two types of chromosome 1p losses with opposite significance in gliomasAnnals of Neurology, 2005
- Chromosome 1p loss: A favorable prognostic factor in low‐grade gliomasAnnals of Neurology, 2005
- Analysis of array CGH data: from signal ratio to gain and loss of DNA regionsBioinformatics, 2004